|
Showing 1 - 1 of
1 matches in All Departments
With the increasing use of immune checkpoint inhibitors (ICI)
across various cancers, the trends for indication at earlier
stages, and the use of combination immunotherapy, the frequency of
ICI-induced immune-related adverse events (irAE) is expected to
grow substantially. Management of these irAE is challenging as it
requires not only consideration of the toxicity but also
risk-benefit ratios with respect to the primary cancer. Several
rheumatic irAE have been reported with ICI therapy including
arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like
manifestations, and several other less common systemic autoimmune
features commonly associated with connective tissue disease. This
handbook provides clinicians with a comprehensive overview of the
management of rheumatic irAE that develop from cancer
immunotherapy. It focuses on the irAE seen with ICI, the most
frequently used agents in treating cancer. It provides an overview
of cancer immunology, immunotoxicity, and immunotherapies such as
ICI, cytokine-based therapy, and CART. It examines the
epidemiology, clinical manifestations, diagnosis, differential
diagnosis, and treatment of a variety of rheumatic immune-related
adverse events arising from these therapies. Chapters also cover
cancer immunotherapy in patients with preexisting rheumatic
diseases such as inflammatory arthritis and other connective tissue
disorders. The book helps clinicians to distinguish the current
types of cancer immunotherapy and general toxicity patterns,
recognize and diagnose rheumatic clinical syndromes, understand the
pathogenesis of irAE, and consider risk-benefit ratios when
managing patients with rheumatic irAE. Rheumatic Diseases and
Syndromes Induced by Cancer Immunotherapy is an essential resource
for physicians and related professionals, residents, fellows,
graduate students and nurses alike in rheumatology, clinical
immunology, oncology, and internal medicine.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.